诺和诺德，暴跌超16%

Group 1 - Novo Nordisk's new weight loss drug CagriSema showed a weight reduction of 23% over 84 weeks, which is less effective than Eli Lilly's drug tirzepatide, which achieved a 25.5% reduction [2] - Following the announcement, Novo Nordisk's stock plummeted over 16%, marking its lowest point since June 2021 and erasing all gains from the launch of its previous weight loss drug, semaglutide [2] - The year 2026 is critical for Novo Nordisk as its semaglutide patent is set to expire in China, leading to the potential entry of numerous generic competitors [2] Group 2 - Analysts indicate that CagriSema is expected to contribute significantly to Novo Nordisk's growth, with estimates suggesting it could account for 60% of the company's future growth [3] - The failure of the clinical data for CagriSema is viewed as a major setback that may dampen demand and weaken long-term sales expectations for Novo Nordisk [3] - CagriSema combines the components Cagrilintide and semaglutide, administered via weekly injections [3] Group 3 - Since reaching its peak market value in 2024, Novo Nordisk has seen a decline of over $470 billion, losing all gains from the launch of semaglutide [4] - Eli Lilly's stock surged following the weak clinical data from Novo Nordisk, bringing its market value close to $1 trillion, with expectations of continued growth in demand for tirzepatide [4] - Eli Lilly plans to launch an oral weight loss drug, orforglipron, in the second quarter of this year, intensifying competition with Novo Nordisk's oral semaglutide [4]